BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 19695319)

  • 1. The Viracept (nelfinavir)--ethyl methanesulfonate case: a threshold risk assessment for human exposure to a genotoxic drug contamination?
    Lutz WK
    Toxicol Lett; 2009 Nov; 190(3):239-42. PubMed ID: 19695319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity.
    Müller L; Gocke E; Lavé T; Pfister T
    Toxicol Lett; 2009 Nov; 190(3):317-29. PubMed ID: 19443141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EMS in Viracept--the course of events in 2007 and 2008 from the non-clinical safety point of view.
    Müller L; Singer T
    Toxicol Lett; 2009 Nov; 190(3):243-7. PubMed ID: 19857794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modelling of patient EMS exposure: translating pharmacokinetics of EMS in vitro and in animals into patients.
    Lavé T; Paehler A; Grimm HP; Gocke E; Müller L
    Toxicol Lett; 2009 Nov; 190(3):310-6. PubMed ID: 19695316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EMS in Viracept--initial ('traditional') assessment of risk to patients based on linear dose response relations.
    Gocke E; Müller L; Pfister T
    Toxicol Lett; 2009 Nov; 190(3):266-70. PubMed ID: 19439165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What happened: the chemistry side of the incident with EMS contamination in Viracept tablets.
    Gerber C; Toelle HG
    Toxicol Lett; 2009 Nov; 190(3):248-53. PubMed ID: 19857795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Literature review on the genotoxicity, reproductive toxicity, and carcinogenicity of ethyl methanesulfonate.
    Gocke E; Bürgin H; Müller L; Pfister T
    Toxicol Lett; 2009 Nov; 190(3):254-65. PubMed ID: 19857796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MNT and MutaMouse studies to define the in vivo dose response relations of the genotoxicity of EMS and ENU.
    Gocke E; Ballantyne M; Whitwell J; Müller L
    Toxicol Lett; 2009 Nov; 190(3):286-97. PubMed ID: 19446969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. General 4-week toxicity study with EMS in the rat.
    Pfister T; Eichinger-Chapelon A
    Toxicol Lett; 2009 Nov; 190(3):271-85. PubMed ID: 19442710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo and in vitro characterization of ethyl methanesulfonate pharmacokinetics in animals and in human.
    Lavé T; Birnböck H; Götschi A; Ramp T; Pähler A
    Toxicol Lett; 2009 Nov; 190(3):303-9. PubMed ID: 19695315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo studies in the mouse to define a threshold for the genotoxicity of EMS and ENU.
    Gocke E; Müller L
    Mutat Res; 2009 Aug; 678(2):101-7. PubMed ID: 19376265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Considerations regarding a permitted daily exposure calculation for ethyl methanesulfonate.
    Müller L; Gocke E
    Toxicol Lett; 2009 Nov; 190(3):330-2. PubMed ID: 19857798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Viracept-EMS case: impact and outlook.
    Walker VE; Casciano DA; Tweats DJ
    Toxicol Lett; 2009 Nov; 190(3):333-9. PubMed ID: 19866516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo genotoxicity of EMS: statistical assessment of the dose response curves.
    Gocke E; Wall M
    Toxicol Lett; 2009 Nov; 190(3):298-302. PubMed ID: 19857797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategy for genotoxicity testing: hazard identification and risk assessment in relation to in vitro testing.
    Thybaud V; Aardema M; Clements J; Dearfield K; Galloway S; Hayashi M; Jacobson-Kram D; Kirkland D; MacGregor JT; Marzin D; Ohyama W; Schuler M; Suzuki H; Zeiger E;
    Mutat Res; 2007 Feb; 627(1):41-58. PubMed ID: 17126066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-linear dose-response of DNA-reactive genotoxins: recommendations for data analysis.
    Johnson GE; Doak SH; Griffiths SM; Quick EL; Skibinski DO; Zaïr ZM; Jenkins GJ
    Mutat Res; 2009 Aug; 678(2):95-100. PubMed ID: 19467345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trace determination of ethyl methanesulfonate in Viracept 250 mg tablets by gas chromatography-mass spectrometry.
    Rebiere H; Maggio AF; Gimeno P; Levaillant D; Civade C; Bonnet PA; Tissier MH
    Pharmeur Sci Notes; 2008 Feb; 2008(1):17-20. PubMed ID: 18430402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-methylpurine DNA glycosylase plays a pivotal role in the threshold response of ethyl methanesulfonate-induced chromosome damage.
    Zaïr ZM; Jenkins GJ; Doak SH; Singh R; Brown K; Johnson GE
    Toxicol Sci; 2011 Feb; 119(2):346-58. PubMed ID: 21071726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statistical model to estimate a threshold dose and its confidence limits for the analysis of sublinear dose-response relationships, exemplified for mutagenicity data.
    Lutz WK; Lutz RW
    Mutat Res; 2009 Aug; 678(2):118-22. PubMed ID: 19477296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative dose-response analysis of ethyl methanesulfonate genotoxicity in adult gpt-delta transgenic mice.
    Cao X; Mittelstaedt RA; Pearce MG; Allen BC; Soeteman-Hernández LG; Johnson GE; Bigger CA; Heflich RH
    Environ Mol Mutagen; 2014 Jun; 55(5):385-99. PubMed ID: 24535894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.